Metformin may help reduce the risk of non-severe statin muscle pain, according to a secondary data analysis of the ACCORD trial.
Statin-associated muscle pain can hinder medication adherence which could potentially lead to an increased risk of cardiovascular events. Currently, there are no approved treatments for statin-associated muscle pain.
For this study, researchers sought to determine the impact of metformin on statin-associated muscle symptoms by analyzing data from the ACCORD trial. They evaluated patients for muscle cramps and leg/calve pain while walking, a common non-severe statin-associated muscle pain symptom, and compared muscle pain among patients taking a statin (n=445) or a statin + metformin (n=869) at baseline.
Compared to statin-only users, the unadjusted data indicated fewer reports of muscle cramps (35% vs 42%) and walking leg/calve pain (40% vs 47%) among statin + metformin users. The researchers calculated a 23% reduced risk of muscle cramps (P=0.046) and a 29% reduced risk of leg/calve pain while walking (P=0.01) based on multivariable regression analysis.
“Metformin appears to reduce the risk of non-severe statin muscle pain,” the researchers concluded. “Additional research is needed to confirm the finding and assess metformin’s impact on statin adherence and related cardiovascular outcomes.”
For more information visit wiley.com.
This article originally appeared on MPR